The Potential of CAR-Modified T Cells in Hematologic Cancers
Renier J. Brentjens, MD, PhD, discusses the potential of using CAR-modified T cells to treat hematologic cancers.
Renier J. Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan-Kettering Cancer Center, discusses the potential of using CAR-modified T cells to treat hematologic cancers.
Clinical Pearls
- If utilized in the proper context, CAR-modified T cells have a role in the treatment of CLL
- CAR-modified T cells have the potential to become the standard of care for the treatment of relapsed B-cell acute lymphoblastic leukemia (ALL)
- Researchers are still learning how to optimize the best way of infusing the cells to get the best response rates
- Pharmaceutical companies are starting to gain interest in cellular therapies because of its potential to treat B-cell cancers as well as other types of cancer
Related Videos
Related Content
Novel Approaches Focus on Limiting Toxicity in Older Patients With ALL
April 22nd 2024Article
The major challenges for clinicians treating older patients with acute lymphoblastic leukemia surround the emergence of resistance to existing therapies and the toxicities associated with current chemotherapies.
Read More
